Piperacillin And Tazobactam Injection, Powder, Lyophilized, For Solution
NDC Package 71357-023-01
Package Information
Piperacillin And Tazobactam injection is the usual total daily dosage of Piperacillin and tazobactam for injection for adult patients with indications other than nosocomial pneumonia is 3.375 g every six hours [totaling 13.5 g (12.0 g piperacillin and 1.5 g tazobactam], to be administered by intravenous infusion over 30 minutes. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Milla Pharmaceuticals Inc., this product is identified by NDC 71357-023 and is authorized under FDA application ANDA207848.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 71357 - Milla Pharmaceuticals Inc.
- 71357-023 - Piperacillin And Tazobactam
- 71357-023-01 - 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON / 60 mL in 1 VIAL, PHARMACY BULK PACKAGE
- 71357-023 - Piperacillin And Tazobactam
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71357-023-01 identifies a specific commercial package of 1 vial, pharmacy bulk package in 1 carton / 60 ml in 1 vial, pharmacy bulk package of Piperacillin And Tazobactam, a human prescription drug labeled by Milla Pharmaceuticals Inc.. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains piperacillin sodium; tazobactam sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Milla Pharmaceuticals Inc. on August 01, 2019. The current certification is valid through December 31, 2027.
How is this Milla Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71357002301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.